The scientific report from the first pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures performed in the eastern part of Central Europe

Maciej Nowacki and Wojciech Zegarski

Abstract
Objective: To perform a single-centre, detailed analysis of the preparations for the introduction of the first pressurized intraperitoneal aerosol chemotherapy (PIPAC) programme in the eastern part of Central Europe.

Methods: The study analysed the 14-month preparation period prior to the performance of the first PIPAC procedure with respect to: (i) general preparations; (ii) patient referral and qualification; (iii) the first PIPAC procedure; (iv) the 2 weeks following PIPAC programme establishment; and (v) general problematic issues that arose.

Results: The length of time needed to prepare our institution for the first PIPAC procedure was extremely long compared with other European Union PIPAC centres: 14 months versus a standard 3–6 months of preparation. The longest amount of time (12 months) was required to prepare the required paperwork.

Conclusions: A new PIPAC programme was successfully established in the eastern part of Central Europe. The length of time to implement this method was significantly longer because of lengthy bureaucratic processes. These current findings should help new centres, especially in this part of Europe, to establish a PIPAC programme more quickly.
Introduction

Peritoneal carcinomatosis (PC) is a devastating diagnosis characterized by a rapidly progressing metastatic process derived from different types of primary neoplasms involving the peritoneal cavity, which is commonly classified and treated as stage IV.\textsuperscript{1–3} The most common primary tumours that metastasize to the peritoneal cavity include ovarian and digestive-tract cancers.\textsuperscript{4,5} For many years, gastroenterologists and surgical oncologists considered PC to be a considerable challenge. As PC was considered to be the terminal stage of the disease, patients were referred for palliative treatment with only a modest portfolio of therapeutic options.\textsuperscript{2,6,7} This situation had arisen because patients with PC and a gastrointestinal primary tumour have a poor prognosis with a relatively short median survival time compared with other types of metastasis.\textsuperscript{8} Notably, the median time of survival for patients receiving only supportive care and standard palliative treatment has been estimated as 1–3 months for patients suffering from PC of gastric cancer origin, 16–17 months for patients with PC of colorectal cancer origin receiving only systemic chemotherapy and 14–24 months for patients with PC of ovarian origin.\textsuperscript{9–12}

The approach to PC has changed since the 1980s, after the implementation of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC), which was introduced experimentally by Spratt, introduced clinically by Sugarbaker, and promoted by a number of clinicians belonging mostly to the Peritoneal Surface Oncology Group International over the last 15 years.\textsuperscript{13,14} The CRS + HIPEC method is now a well-established treatment worldwide for PC with a mean per capita number of procedures of 15 patients/1 million per year.\textsuperscript{15} Nevertheless, despite the excellent success of the CRS + HIPEC method, there are still patients with PC who cannot be treated with CRS + HIPEC due to a high PC index or because their physical condition only allows for a minimally invasive procedure without aggressive debulking. Another problem is that some patients initially require more than one cycle of specific intraperitoneal chemotherapy.\textsuperscript{16–18}

On the 5th of November 2011, Reymond first performed and introduced a new PC treatment technique to the clinic, known as pressurized intraperitoneal aerosol chemotherapy (PIPAC), which became a promising therapeutic method for this group of patients that offered the potential to solve many of the previously unresolved problems associated with CRS + HIPEC.\textsuperscript{19} To date, many HIPEC centres have added PIPAC as a therapeutic option. Currently, the PIPAC procedure is performed in nearly 30 countries, mostly in Western Europe, in a total of 100 highly specialized treatment centres.\textsuperscript{20} For many countries, such as Italy, France and Denmark, implementation of this novel drug delivery technique occurred only within the last 2 years, in a smooth implementation period lasting 3–6 months. Many institutions worldwide are now preparing to undertake their first PIPAC procedure.\textsuperscript{21,22} To the best of our knowledge, based on a careful review of
the literature and documentation through to May 2017 pertaining to the supply of specialized medical equipment necessary for PIPAC, no PIPAC procedures have been performed in the eastern part of Central Europe. This region includes the Visegrád countries such as the Czech Republic, Hungary, Poland and Slovakia. We are also not aware of any publications that have addressed the preparations involved in establishing a new PIPAC centre in this region.

The aim of this current study was to perform a retrospective, single-centre, detailed analysis of the preparations for performing the first PIPAC procedure at a surgical oncology centre in Bydgoszcz, Poland. This current report describes the major delays and other limitations that were encountered during the preparations and how these were resolved. It is our expectation that this current report will enable other institutions to implement PIPAC programmes in a timely manner without any unnecessary delays, possibly by eliminating some of the problematic aspects that are discussed herein.

Methods

This retrospective study analysed the period of 14 months \((n = 14)\) prior to 10 May 2017 when the first patients underwent a PIPAC procedure in the Department of Surgical Oncology, Ludwik Rydygier’s Collegium Medicum, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland. In addition, the study analysed the day of the first PIPAC surgery and the first 2 weeks after establishment of the PIPAC programme. The findings and analyses have been divided into five sections: (i) general preparations for the first PIPAC procedure; (ii) patient referral and qualification; (iii) the first PIPAC procedure; (iv) the 2 weeks following establishment of the PIPAC programme; and (v) general problematic issues that arose during preparation for the PIPAC procedures and how these were resolved. In these five sections, the following issues were analysed: practical aspects (including the surgical learning curve for PIPAC); creation of the multidisciplinary (MDT)-PIPAC team; obtaining the required paperwork, such as approvals and required permits; organization of the operating theatre and acquisition of the required equipment; patient recruitment and selection; and any other additional steps deemed essential to the establishment of the PIPAC programme at our institution. The fifth section, listed as general problematic issues, describes the most problematic issues and critical points that arose during preparation for the PIPAC procedures, of preparations that occurred in our institution for the procedure, including important turning points and the solutions used to resolve the problems that occurred.

All patients gave voluntary and informed consent to the planned treatment and the study was performed in accordance with the Declaration of Helsinki. Consent for all steps in this study were obtained from the Oncology Review Board of Ludwik Rydygier’s Collegium Medicum.

Results

General preparations for the first PIPAC procedure

This study evaluated the distribution of the amount of time spent on the key steps during the preparation for the first PIPAC procedure to be undertaken in the Department of Surgical Oncology, Ludwik Rydygier’s Collegium Medicum, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland. These time periods are presented in Figure 1 and include the following: (i) the process of making a decision to establish the PIPAC procedure (2 months); (ii) an extensive literature review (7 months); (iii) the participation in international PIPAC
meetings and workshops (4 months); (iv) visits to professional PIPAC centres (1 month); (v) the establishment of the MDT-PIPAC team (5 months); (vi) the completion of the required documents, approvals and certificates (12 months); (vii) the acquisition of the required instruments and equipment (7 months); (viii) the preparation of information, materials, tutorials and collection of patient consents, including their approval (4 months); (ix) the recruitment of candidate patients for the procedure and selection of the patients (3 months); (x) the oncological MDT evaluation of qualified patients with detailed analysis of all of their possible therapeutic options (1 month); and (xi) the preparation of patient specimens with histological and immunohistochemical evaluation by the Department of Anatomical Pathology, Ludwik Rydygier’s Collegium Medicum (1 month). As a result, a checklist based on the key preparation steps is presented in Table 1.

The authors attended one international PIPAC meeting held in Baltimore, Maryland, USA and one PIPAC workshop held in Lausanne, Switzerland. The authors visited two different PIPAC centres: (i) CHUV Lausanne University Hospital in Switzerland, while they attended the workshop; and (ii) Centre Hospitalier Lyon Sud in France, which supplied the possibility for active surgery assistance.

Formation of the MDT-PIPAC team started 9 months before the first PIPAC procedure and comprised of a team of 11 people with the skills and/or responsibilities that are detailed in Table 2. The longest step, which lasted approximately 1 year, involved completing the required paperwork, which entailed the collection and analysis of documents related to occupational health and safety, medical permits, certificates for all of the required equipment, protocol/procedure description materials, patient consents and legal approvals. The selection and ordering of required materials and tools were possible after attending the PIPAC workshop and meeting; four independent suppliers of medical equipment were needed.
To determine which patients qualified for the PIPAC procedure, a thorough review of the scientific literature was undertaken in conjunction with the existing knowledge base and experience gained from being a HIPEC centre. Two qualification/recommendation criteria lists were developed (Tables 3 and 4) and shared with medical oncologists and surgical oncologists at the Ludwik Rydygier’s Collegium Medicum as part of a call for patient referrals. The two lists called for patients in good clinical condition who qualified for a minimally invasive surgical procedure and who had a confirmed PC status with the PC originating from colorectal cancer, gastric cancer, ovarian cancer, appendiceal cancer, gallbladder cancer, pancreatic cancer, pseudomyxoma peritonei and peritoneal mesothelioma. After a 3-month evaluation period, two patients (male: 72 years; female: 49 years) with a PC of gastric cancer origin who met all the inclusion criteria were selected.

### Patient referral and qualification

To determine which patients qualified for the PIPAC procedure, a thorough review of the scientific literature was undertaken in conjunction with the existing knowledge base and experience gained from being a HIPEC centre. Two qualification/recommendation criteria lists were developed (Tables 3 and 4) and shared with medical oncologists and surgical oncologists at the Ludwik Rydygier’s Collegium Medicum as part of a call for patient referrals. The two lists called for patients in good clinical condition who qualified for a minimally invasive surgical procedure and who had a confirmed PC status with the PC originating from colorectal cancer, gastric cancer, ovarian cancer, appendiceal cancer, gallbladder cancer, pancreatic cancer, pseudomyxoma peritonei and peritoneal mesothelioma. After a 3-month evaluation period, two patients (male: 72 years; female: 49 years) with a PC of gastric cancer origin who met all the inclusion criteria were selected.

### The first PIPAC procedure

A single laparoscopic operating room equipped with laminar airflow was prepared...
for the first PIPAC procedure. One day before the procedure, all the required instruments and devices were tested and an inventory of all the required tools was thoroughly double-checked. One day before the procedure, a final briefing with all MDT-PIPAC members was organized. For each PIPAC procedure (one surgery for each patient), two different laparoscopic (LAP) sets were sterilized and prepared, including a 5 mm (30°C) Olympus Autoclavable Laparoscope (Olympus, Tokyo, Japan). Thus, four LAP sets were prepared; two were designated for use in surgery and the other two were designated reserve LAP sets. Each LAP set additionally included one 5 mm and one 12 mm Kii blunt tip double balloon secured access trocar (Applied Medical, Rancho Santa Margarita, CA, USA), one CapnoPen laparoscopic nebulizer (Capnomed, Villingendorf, Germany) and one standard suction device. A double syringe Accutron HP-D Injector (Medtron AG, Saarbrücken, Germany) was used as the injection device during the PIPAC surgery.

During surgery, the patient was placed in the supine-basic position with extended and maintained legs. At the beginning of the surgery, the Veress-needle technique was used to establish a 12 mmHg capnoperitoneum. Four biopsies were performed for each patient with an additional local peritonectomy. The chemotherapy agents, 7.5 mg/m² cisplatin and 1.5 mg/m² doxorubicin, were used as suggested by several PIPAC centres, for 30 min at 37°C. The total operating time was 108 min for the first patient and 96 min for the second patient. The toxic aerosol was released safely via a closed aerosol waste system.

**The 2 weeks following establishment of the PIPAC programme**

Regional oncologists were informed about the preparations for the first procedure at

---

**Table 3.** Qualification criteria for the pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedure according to the clinical status and presentation of peritoneal carcinomatosis (PC) based on the current PIPAC procedure standards.23

| Patients with too high PC index for cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) |
| Patients primarily disqualified from CRS + HIPEC for any reason (i.e. too high PC index, temporary disqualification criteria) in which PIPAC could be used as a neoadjuvant ‘bridge’ therapy |
| Patients with radiological or intraoperatively confirmed PC |
| Patients with PC in which diagnostic laparoscopy excluded the possibility of another aggressive form of therapy |
| Patients who, due to PC development, may require more than one course of specialized intraperitoneal chemotherapy |
| Patients who can only undergo minimally invasive surgery because of their clinical condition |
| Patients with PC without other types of metastases |
| Patients in a good clinical condition or with those that have the clinical possibility of the safe management of their accompanying morbidities |
| Patients with the correct American Society of Anesthesiologists score to allow for the safe implementation of laparoscopy |

**Table 4.** The list of recommended tumours of origin of the peritoneal carcinomatosis (PC) for patients being referred for the pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedure.

| Tumour origin | Tumour origin |
|---------------|--------------|
| 1 Colorectal cancer | 1 Colorectal cancer |
| 2 Gastric cancer (including Krukenberg tumour) | 2 Gastric cancer (including Krukenberg tumour) |
| 3 Ovarian cancer | 3 Ovarian cancer |
| 4 Pseudomyxoma peritonei | 4 Pseudomyxoma peritonei |
| 5 Peritoneal mesothelioma | 5 Peritoneal mesothelioma |
| 6 Appendiceal cancer | 6 Appendiceal cancer |
| 7 Gallbladder cancer | 7 Gallbladder cancer |
| 8 Pancreatic cancer | 8 Pancreatic cancer |
the beginning of the programme implementation. During this period, the authors started to look for potential patients that could be referred for the PIPAC procedure. During the 2 weeks following the successful performance of the first PIPAC procedure, the number of patient referrals increased. The number of regional medical oncologists referring their patients for the PIPAC procedure increased from one who was interested initially in the procedure to 24 who were interested in referring their patients for the PIPAC procedure by the end of the first 2 weeks. There were also new groups of medical specialists referring their patients for the procedure including general surgeons, general practitioners, gastroenterologists and gynaecologists. There were also some return referrals from palliative care specialists. Before the first PIPAC procedure, oncological surgeons (33 of 34; 97%) were the primary referrers.

General problematic issues

The time that it took the Ludwik Rydygier’s Collegium Medicum to prepare for the first PIPAC procedure was extremely long compared with other European Union PIPAC centres: 14 months versus a standard 3–6 months of preparation. During general preparations for the first PIPAC procedure, three key problems arose. The first occurred at the time that the institution decided to establish a PIPAC programme. Establishing this procedure for the first time in the eastern part of Central Europe had some inherent difficulties, most notably a lack of regional scientific and technical expertise in the PIPAC procedure and familiarity/experience with the efficient and timely establishment of the technique. This issue was resolved by our active participation in a PIPAC meeting and workshop and by visiting PIPAC centres. A second major issue involved the acquisition of the required devices and tools for the procedure. The primary contacts and vendors for the required equipment were not represented in the eastern part of Central Europe. In addition, due to Polish medical safety and anticorruption regulations, it was not possible to simply order all of the required equipment via another country such as Germany or Switzerland. This problem was resolved in two ways. First, the main company headquarters of the equipment were contacted to obtain information about any possible Polish representatives. Secondly, we appealed for representation in Poland by these companies and for assistance in obtaining any needed permits, approvals and certificates. This particular issue was a rate-limiting factor in the preparations because it took 7 months to acquire the necessary equipment and associated paperwork. The last major issue entailed patient recruitment and the number of patients qualifying for PIPAC as well as the relatively small initial response to our call for patients from medical oncologists (one of 34; 3%) compared with the very high response from surgical oncologists (33 of 34; 97%). This problem was resolved with several informational campaigns and the creation of rigorous and clear qualification criteria.

Discussion

The PIPAC technique has become an important, innovative method of drug delivery that offers hope to patients suffering from PC, who due to some limitation(s) cannot be treated using other methods, such as CRS + HIPEC.25 This hope has been supported by a growing number of published clinical and preclinical studies in the field of PC treatment indicating that PIPAC is highly efficient.23,26

The implementation of any new and especially innovative technique is not simple.27,28 This situation is well observed in specific medical specialties such as...
oncology and surgery.\textsuperscript{29,30} On 10 May 2017, two patients underwent PIPAC procedures performed for the first time in the Department of Surgical Oncology, Ludwik Rydygier’s Collegium Medicum, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland. The intensive preparations for this procedure lasted for over 1 year (14 months) and consisted of several important steps. The time of implementation was significantly longer than in other centres because of bureaucratic problems related mainly to the organization of paperwork and the first use of specific medical devices and surgical tools in Poland.

At the beginning of the process of establishing PIPAC at our institution, as in many cases wherein a new treatment technique is implemented, our first contact with PIPAC occurred through an extensive analysis of the literature using the standard public bibliographic database PubMed.\textsuperscript{27} The preparation stage required the most time (12 months) during the establishment of PIPAC and involved completing the required paperwork, such as obtaining approvals and certificates. Indeed, increased administrative and bureaucratic requirements appear to be a limitation experienced around the globe for implementing new therapeutic procedures.\textsuperscript{31} An important preparation step, which accelerated the learning curve, was the authors’ participation in a PIPAC workshop (4 months) and visits to other PIPAC centres (1 month), which increased the probability of success. While the importance of carefully planned preparation steps for establishing PIPAC is self-evident, the literature supports that methodical preparation in the implementation of new therapies positively impacts the safety and feasibility of the planned procedure, obtains positive therapeutic effects, improves the learning curve for the procedure and facilitates the acquisition of a strong knowledge base and understanding of the principles of the technique, all of which are critical for good medical practice.\textsuperscript{32} The final number of individuals in the MDT-PIPAC team was 11, which contrasts with the standard number of individuals involved in a PIPAC procedure (usually only two surgeons, two scrub nurses and one anaesthetist).\textsuperscript{33} The increased number of personnel on our team was due to the need to create a unified team responsible for the assessment of patient qualification, the performance of the procedure and the assessment of the outcome. Overall, in our opinion, the early formation of the interdisciplinary team during the preparation phase was essential to the success of the procedure and appears to be in line with current trends in surgical oncology.\textsuperscript{34}

Our two main qualification criteria for PC patients were related to factors associated with the condition of the patient and to the aetiology of the cancer. This biphasic qualification methodology was formulated based on the literature and was consistent with the qualification criteria used by other PIPAC centres that aim to precisely determine eligibility for the procedure.\textsuperscript{35,36} We recommend strict adherence to published standard PIPAC protocols, as we did during the performance of our first PIPAC procedure. We believe that this adherence will not only satisfy important legal and safety considerations but also enable the acquisition of uniform data from among PIPAC centres, as demonstrated by historical examples, such as the introduction of robotic techniques in surgery.\textsuperscript{37,38}

The 2 weeks following the successful PIPAC procedure were particularly interesting. Starting the day after the surgery, there was a marked increase in the number of inquiries for PIPAC surgery. Our general call centre was unprepared for the high number of calls by patients with cancer metastases other than PC seeking information about PIPAC. We remedied this by creating PIPAC and PC instructional tutorials and by introducing broad media campaigns
using the internet and social media to widen our reach of patients and their families.\textsuperscript{39} There were also a significantly higher percentage of patients referred for PIPAC by medical oncologists, which is a group of specialists who initially responded poorly to our call for potential patients for PIPAC surgery. We speculate this change may have been due to an effect described by Kleinrock termed ‘challenging choices’ in oncology innovation, wherein healthcare professionals opt to wait for the positive effects or success of an innovative treatment to be realized before introducing it to their patients because of a fear of responsibility and/or funding concerns.\textsuperscript{40} Another factor driving the change may be related to the curiosity sparked by the success of our first PIPAC procedure, coupled with the underlying hope and desire to find a novel PC treatment possibility.\textsuperscript{41}

In conclusion, this current report has described the successful establishment of a new PIPAC programme. The time taken to implement this new methodology was significantly longer than in some other PIPAC centres, probably due to the long bureaucratic processes involved. We anticipate that our findings will help new centres, especially in this part of Europe, to more quickly implement PIPAC programmes, through the elimination of the major problems that we experienced and discussed.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**References**

1. Glehen O, Mohamed F and Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. *Lancet Oncol* 2004; 5: 219–228.
2. Nowacki M, Wisniewski M, Werengowska-Cieciewicz K, et al. Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: a multidisciplinary study of peritoneal carcinomatosis. *Oncotarget* 2015; 6: 22776–22798.
3. Macı` A, Saladino E, Bartolo V, et al. Peritoneal carcinomatosis of colorectal origin. *World J Gastrointest Oncol* 2010; 2: 98–101.
4. Beaujard AC, Glehen O, Caillot JL, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. *Cancer* 2000; 88: 2512–2519.
5. Robella M, Vaira M, Marsanic P, et al. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). *Minerva Chir* 2014; 69: 27–35.
6. Li Y, Zhou YF, Liang H, et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. *World J Gastroenterol* 2016; 22: 6906–6916.
7. Sano T. Is peritoneal carcinomatosis an incurable disease or controllable locoregional condition? Challenge of surgeons with intraperitoneal hyperthermic chemotherapy. *Jpn J Clin Oncol* 2001; 31: 571–572.
8. Terzi C, Arslan NC and Canda AE. Peritoneal carcinomatosis of gastrointestinal tumors: where are we now? *World J Gastroenterol* 2014; 20: 14371–14380.
9. Montori G, Coccolini F, Ceresoli M, et al. The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art. *Int J Surg Oncol* 2014; 2014: 912418.
10. Klaver YL, Lemmens VE, Nienhuijs SW, et al. Peritoneal carcinomatosis of colorectal origin: Incidence, prognosis and treatment options. *World J Gastroenterol* 2012; 18: 5489–5494.
11. Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 2016; 17: 1709–1719.

12. Castro-Mestaa JF, Gonzalez-Guerreroa JF, Barrios-Sánchezb P, et al. Bases and foundations of the treatment of peritoneal carcinomatosis: Review article. Medicina Universitaria 2016; 18: 98–104.

13. Neuwirth MG, Alexander HR and Karakousis GC. Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. J Gastrointest Oncol 2016; 7: 18–28.

14. Goéré D, Passot G, Gelli M, et al. Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). Int J Hyperthermia 2017; 33: 550–527.

15. Verwaal VJ, Rau B, Jamali F, et al. Registries on peritoneal surface malignancies through out the world, their use and their options. Int J Hyperthermia 2017; 33: 528–533.

16. Tempfer CB, Hartmann F, Hilal Z, et al. Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report. BMC Cancer 2017; 17: 26.

17. Ng JL, Ong WS, Chia CS, et al. Prognostic Relevance of the Peritoneal Surface Disease Severity Score Compared to the Peritoneal Cancer Index for Colorectal Peritoneal Carcinomatosis. Int J Surg Oncol 2016; 2016: 2495131.

18. Girshally R, Demtröder C, Albayrak N, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2016; 14: 253.

19. Solass W, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol 2013; 20: 3504–3511.

20. Teixeira Farinha H, Grass F, Kelleyesus A, et al. Impact of Pressurized Intraperitoneal Aerosol Chemotherapy on Quality of Life and Symptoms in Patients with Peritoneal Carcinomatosis: A Retrospective Cohort Study. Gastroenterol Res Pract 2017; 2017: 4596176.

21. Robella M, Vaira M and De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinoma. World J Surg Oncol 2016; 14: 128.

22. Graversen M, Pfeiffer P and Mortensen MB. Treatment of peritoneal carcinomatosis with pressurized intraperitoneal aerosol chemotherapy. Ugeskr Laeger 2016; 178: pii: V11150928 [In Danish, English abstract].

23. Grass F, Vuagniaux A, Teixeira-Farinha H, et al. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg 2017; 104: 669–678.

24. Nadiradze G, Giger-Pabst U, Zieren J, et al. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis. J Gastrointest Surg 2016; 20: 367–373.

25. Sleeman JP. PIPAC puts pressure on peritoneal metastases from pancreatic cancer. Clin Exp Metastasis 2017; 34: 291–293.

26. Graversen S, Detlefsen S, Bjerregaard JK, et al. Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Clin Exp Metastasis 2017; 34: 309–314.

27. Nowacki M, Nazarewski Ł, Kloskowski T, et al. Novel surgical techniques, regenerative medicine, tissue engineering and innovative immunosuppression in kidney transplantation. Arch Med Sci 2016; 12: 1158–1173.

28. Nowacki M, Pietkun K, Jundzill A, et al. Use of Adipose-Derived Stem Cells to Support Topical Skin Adhesive for Wound Closure: A Preliminary Report from Animal In Vivo Study. Biomed Res Int 2016; 2016: 2505601.
29. Habib SL, Al-Obaidi NY, Nowacki M, et al. Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients? *J Cancer* 2016; 7: 1621–1631.

30. Neugebauer EA, Becker M, Buess GF, et al. EAES recommendations on methodology of innovation management in endoscopic surgery. *Surg Endosc* 2010; 24: 1594–1615.

31. Field RI. Why is health care regulation so complex? *PT* 2008; 33: 607–608.

32. Healey P and Samanta J. When does the ‘learning curve’ of innovative interventions become questionable practice? *Eur J Vasc Endovasc Surg* 2008; 36: 253–257.

33. Hübner M, Grass F, Teixeira-Farinha H, et al. Pressurized IntraPeritoneal Aerosol Chemotherapy – Practical aspects. *Eur J Surg Oncol* 2017; 43: 1102–1109.

34. Abdulrahman GO Jr. The effect of multidisciplinary team care on cancer management. *Pan Afr Med J* 2011; 9: 20.

35. Tempfer CB, Reznicek GA, Ende P, et al. Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin in women with peritoneal carcinomatosis: a cohort study. *Anticancer Res* 2015; 35: 6723–6729.

36. Demtröder C, Solass W, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. *Colorectal Dis* 2016; 18: 364–371.

37. Cox DR. The design of empirical studies: towards a unified view. *Eur J Epidemiol* 2016; 31: 217–228.

38. Zureikat AH, Postlewait LM, Liu Y, et al. A Multi-institutional Comparison of Perioperative Outcomes of Robotic and Open Pancreaticoduodenectomy. *Ann Surg* 2016; 264: 640–649.

39. Falisi AL, Wiseman KP, Gaysynsky A, et al. Social media for breast cancer survivors: a literature review. *J Cancer Surviv* 2017; 11: 808–821.

40. Kleinrock M. Oncology innovation and challenging choices: balancing value and funding priorities in light of an abundance of new treatment options. *Am Health Drug Benefits* 2015; 8: 196–199.

41. Sugarbaker P. Pharmacology of chemotherapy treatments for peritoneal metastases: optimizing and augmenting HIPEC. *Pleura and Peritoneum* 2017; 2: 43–45.